NCT Number: NCT07112846
Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an extremely concerning scenario from both epidemiological and healthcare perspectives. In addition to this, the reemergence of childhood exanthematous diseases in several countries, including Brazil, is alarming and occurs due to declining vaccination coverage and increased migratory movements. These diseases present overlapping clinical symptoms, and their differential diagnosis is often challenging, which, in a context of dengue and Chikungunya epidemics like the current one, may lead to underreporting of diseases such as measles and rubella. This project aims to build a prospective registry of the occurrence of dengue, Chikungunya, measles, and rubella in various healthcare centers in Brazil, in order to better understand the epidemiological scenario, identify clinical variables associated with different diagnoses, and describe healthcare bottlenecks that may hinder proper reporting and identification of these diseases.
Trial opening soon.
Get NotifiedUp to 18 year
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Individuals from newborns (zero years old) to 18 years of age, of both sexes.
Suspected individuals with the following criteria:
Measles: Presenting fever and rash associated with cough and/or runny nose and/or conjunctivitis, regardless of age or vaccination status;
Rubella: Presenting fever, rash, and lymphadenopathy, regardless of age or vaccination status;
Dengue and Chikungunya: Presenting myalgia, arthralgia, headache, retro-orbital pain, nausea, vomiting, rash, petechiae, positive tourniquet test, or leukopenia and/or lymph node enlargement;
Individuals who, meeting the above criteria, underwent sample collection for viral panel testing for the differential diagnosis of exanthematous diseases."
Exclusion criteria
-
Time frame: From enrollment to the end of follow-up (30 days).
Prevalence of positive infections for one or more infectious diseases (rubella, measles, dengue, and Chikungunya)
Contact information is provided by the study sponsor or research team.
Henrique R A da Fonseca, PhD
CONTACT
Karina Tozatto Maio, MD, PhD
CONTACT
Hospital Israelita Albert Einstein
Other
Acronym: CRIUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03102905
Exanthema, HHV6
Amiens, Picardie, France
View Trial DetailsNCT06399029
Exanthema, Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
Zurich, Switzerland
View Trial DetailsNCT07358910
Adenophorea Infections, Adenoviridae Infections
Phnom Penh, Cambodia
View Trial DetailsNCT07338851
Central Nervous System Diseases, Central Nervous System Infections
Suzhou, Anhui, China
View Trial Details